RPRX vs. JNJ
Compare and contrast key facts about Royalty Pharma plc (RPRX) and Johnson & Johnson (JNJ).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: RPRX or JNJ.
Key characteristics
RPRX | JNJ | |
---|---|---|
YTD Return | 2.81% | 9.09% |
1Y Return | 3.98% | 6.09% |
3Y Return (Ann) | -7.71% | 3.39% |
Sharpe Ratio | 0.14 | 0.44 |
Daily Std Dev | 23.78% | 15.28% |
Max Drawdown | -47.73% | -52.60% |
Current Drawdown | -41.96% | -3.42% |
Fundamentals
RPRX | JNJ | |
---|---|---|
Market Cap | $16.76B | $402.18B |
EPS | $1.50 | $6.62 |
PE Ratio | 18.83 | 25.24 |
PEG Ratio | 15.23 | 0.98 |
Total Revenue (TTM) | $2.24B | $86.58B |
Gross Profit (TTM) | $1.29B | $59.79B |
EBITDA (TTM) | $976.81M | $33.37B |
Correlation
The correlation between RPRX and JNJ is 0.25, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Performance
RPRX vs. JNJ - Performance Comparison
In the year-to-date period, RPRX achieves a 2.81% return, which is significantly lower than JNJ's 9.09% return. The chart below displays the growth of a $10,000 investment in both assets, with all prices adjusted for splits and dividends.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
RPRX vs. JNJ - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Royalty Pharma plc (RPRX) and Johnson & Johnson (JNJ). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
RPRX vs. JNJ - Dividend Comparison
RPRX's dividend yield for the trailing twelve months is around 2.94%, more than JNJ's 2.91% yield.
TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Royalty Pharma plc | 2.94% | 2.85% | 1.92% | 1.71% | 0.60% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Johnson & Johnson | 2.91% | 3.00% | 2.52% | 2.45% | 2.53% | 2.57% | 2.74% | 2.38% | 2.73% | 2.87% | 2.64% | 2.83% |
Drawdowns
RPRX vs. JNJ - Drawdown Comparison
The maximum RPRX drawdown since its inception was -47.73%, smaller than the maximum JNJ drawdown of -52.60%. Use the drawdown chart below to compare losses from any high point for RPRX and JNJ. For additional features, visit the drawdowns tool.
Volatility
RPRX vs. JNJ - Volatility Comparison
Royalty Pharma plc (RPRX) has a higher volatility of 4.94% compared to Johnson & Johnson (JNJ) at 3.34%. This indicates that RPRX's price experiences larger fluctuations and is considered to be riskier than JNJ based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Financials
RPRX vs. JNJ - Financials Comparison
This section allows you to compare key financial metrics between Royalty Pharma plc and Johnson & Johnson. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities